About latigo biotherapeutics inc - LTGO
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded by Bryan Moyer on November 20, 2018 and is headquartered in Thousand Oaks, CA.
LTGO At a Glance
Latigo Biotherapeutics, Inc.
1300 Rancho Conejo Boulevard
Thousand Oaks, California 91320
| Phone | 1-805-716-2927 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -109,167,000.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
LTGO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
LTGO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
LTGO Liquidity
| Current Ratio | 4.002 |
| Quick Ratio | 4.002 |
| Cash Ratio | 3.775 |
LTGO Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -221.929 |
| Return on Equity | -336.738 |
| Return on Total Capital | -189.533 |
| Return on Invested Capital | -333.696 |
LTGO Capital Structure
| Total Debt to Total Equity | 1.212 |
| Total Debt to Total Capital | 1.198 |
| Total Debt to Total Assets | 0.914 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 0.22 |